NCT03135964

Brief Summary

Introduction Negative pressure wound therapy (NPWT), also known as topical negative pressure, has become a popular therapy for the treatment of many acute and chronic wounds. In many randomized controlled trials(RCTs), NPWT also has benefit in diabetic foot ulcer and pressure ulcer. However, most studies used commercial VAC device in combined with polyurethane (PU) foam. It is not yet clear where NPWT combined with gauze as wound filler is as effective as the PU foam. This RCT evaluated the efficacy of the gauze and PU foam, two kinds of fillers routinely used in negative pressure wound therapy, on the healing of the diabetic lower-extremity ulcers and the pressure ulcer. Methods From 2010/1 to 2015/01, the in-patient persons with difficult to heal diabetic ulcer or Grade 4 pressure ulcer were enrolled. These patients were divided into two groups randomly. The letter of consent was signed by the patient or patient's family. After debridement of the infective wound, the wound of experimental group was packed with a moistened Polyhexamethylene biguamide (PHMB) impregnated gauze (Kerlix AMD, Covidien). A noncollapsible drainage tube (Blake drain, Ethicon) was applied to the wound, and then sealed with 3M Tegaderm Film. The system was connected to a 1-bottle water-seal chest drainage system and to standard wall suction at 125 mmHg negative pressure. The dressing was changed at 72- to 96-hour intervals (twice a week) for a period of 3 weeks. To the control group, the PU foam dressing from KCI was packed and sealed to the wound with the same continuous wall suction at -125mmHg. Investigators observed and recorded the ulcer area twice a week on each time of changing dressing in the following 3 weeks. The percentage of wound area reduction(PWAR) was used as a predictor of wound healing. The repeated measuring data were analyzed using linear mixed mode with SPSS statistical software. This clinical study was approved and monitored by Institutional Review Board of Show Chwan Memorial Hospital.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
57

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2011

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2011

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2015

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

November 4, 2015

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2016

Completed
1.2 years until next milestone

First Posted

Study publicly available on registry

May 2, 2017

Completed
Last Updated

May 2, 2017

Status Verified

April 1, 2017

Enrollment Period

3.9 years

First QC Date

November 4, 2015

Last Update Submit

April 26, 2017

Conditions

Keywords

NPWTfoamgauze

Outcome Measures

Primary Outcomes (1)

  • The reduction rate of pressure ulcer size

    up to 3weeks

Secondary Outcomes (1)

  • The reduction rate of diabetic foot ulcer size

    up to 3weeks

Study Arms (2)

foam

ACTIVE COMPARATOR

PU foam dressing from KCI

Device: filler dressing of NPWT

gauze

ACTIVE COMPARATOR

Polyhexamethylene biguamide (PHMB) impregnated gauze (Kerlix AMD, Covidien)

Device: filler dressing of NPWT

Interventions

a dressing or filler material is used to fit to the contours of a wound (which is covered with a non-adherent dressing film) .

Also known as: KCI PU foam dressing, Kerlix AMD gauze
foamgauze

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • in-patient persons with the pressure ulcer or diabetic ulcer

You may not qualify if:

  • Patient who has uncontrolled medical condition, such as sepsis, cellulitis
  • Patient with diabetic ulcer who has severe PAOD untreated

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tainan Municipal Hospital

Tainan, 701, Taiwan

Location

MeSH Terms

Conditions

Pressure UlcerDiabetic Foot

Condition Hierarchy (Ancestors)

Skin UlcerSkin DiseasesSkin and Connective Tissue DiseasesDiabetic AngiopathiesVascular DiseasesCardiovascular DiseasesFoot UlcerLeg UlcerDiabetes ComplicationsDiabetes MellitusEndocrine System DiseasesDiabetic Neuropathies

Study Officials

  • Chao-Chin Yu, Master

    Tainan Municipal Hospital

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 4, 2015

First Posted

May 2, 2017

Study Start

February 1, 2011

Primary Completion

January 1, 2015

Study Completion

March 1, 2016

Last Updated

May 2, 2017

Record last verified: 2017-04

Locations